ADMA Biologics SEC filings

Filter: All · 8-K · 10-Q · 10-K · Form 4

4Nov. 5, 2026, 9:05 p.m. ETView on SEC.gov
10-QNov. 4, 2026, 5:16 p.m. ETView on SEC.gov
8-KNov. 4, 2026, 4:10 p.m. ETView on SEC.gov
Results of operations and financial condition · Financial statements and exhibits
AI summary, unreviewedADMA Biologics Q3 2026 adjusted EPS $0.23 beats $0.20 consensus on $141.1 million revenue; FY2026 revenue floor of $530 million sits below $535.3 million consensus
SCHEDULE 13GAug. 7, 2026, 8:23 a.m. ETView on SEC.gov
10-QAug. 5, 2026, 5:16 p.m. ETView on SEC.gov
8-KAug. 5, 2026, 4:10 p.m. ETView on SEC.gov
Results of operations and financial condition · Financial statements and exhibits
4July 28, 2026, 9 p.m. ETView on SEC.gov